Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 09, 2023 at 04:29 pm EST
Share
Genovate Biotechnology Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 137.06 million compared to TWD 115.35 million a year ago. Net income was TWD 16.99 million compared to TWD 7.02 million a year ago. Basic earnings per share from continuing operations was TWD 0.16 compared to TWD 0.07 a year ago. Diluted earnings per share from continuing operations was TWD 0.16 compared to TWD 0.07 a year ago.
For the nine months, sales was TWD 409.07 million compared to TWD 323.47 million a year ago. Net income was TWD 43.65 million compared to TWD 0.832 million a year ago. Basic earnings per share from continuing operations was TWD 0.4 compared to TWD 0.01 a year ago. Diluted earnings per share from continuing operations was TWD 0.4 compared to TWD 0.01 a year ago.
Genovate Biotechnology Co., LTD. is a Taiwan-based company principally engaged in the research, development, manufacture and sales of pharmaceutical preparations, drug substances and intermediates. The Company's products include nervous system drugs, digestive system drugs, analgesic and anti-inflammatory drugs, urogenital system drugs, antimicrobial drugs, cardiovascular system drugs, acne drugs, antineoplastic drugs and anti-diabetic drugs, as well as healthcare food and cosmetics. The Company is also engaged in the provision of clinical experimental testing services and technology export services. The Company distributes its products mainly within domestic market.
GENOVATE BIOTECHNOLOGY CO., LTD. 
